Anaplastic large cell lymphoma: what patients should know

It may involve lymph nodes, skin or other organs. A biopsy is needed to confirm the diagnosis and distinguish disease confined to the skin from disease affecting the body more widely.

The abnormal cells usually carry a marker called CD30. Laboratory testing also checks for a change involving the ALK protein, because ALK-positive and ALK-negative systemic disease can behave differently and may lead to different treatment discussions. Primary cutaneous disease begins in the skin and is assessed separately from systemic disease that has reached the skin. Night sweats, fever, unexplained weight loss, enlarged lymph nodes or persistent skin lumps can occur, but symptoms alone cannot establish the diagnosis.

A haematology team reviews the biopsy, blood tests and imaging to define the subtype and extent of disease. Treatment may include medicines that kill rapidly dividing cells, antibody-based treatment directed at CD30, radiotherapy for selected local areas or observation after complete removal of a limited skin lesion. For disease that returns or does not respond, the team may discuss a stem cell transplant, other immune-based treatment or a clinical trial. The plan also accounts for symptoms, general health and earlier treatments.

Arrange a medical assessment for a lymph node that remains enlarged, a growing skin lump, unexplained fevers, drenching night sweats or weight loss without trying. If you are receiving treatment, contact the oncology team promptly for fever, shaking chills, new breathlessness, unusual bleeding or an inability to drink. Seek emergency help for severe difficulty breathing, chest pain, confusion or swelling of the face or throat.

Ask whether the lymphoma is primary cutaneous or systemic, whether the cells are ALK-positive, what the scan shows, and what the goal of treatment is. It is also useful to discuss how treatment could affect fertility, infection risk and daily activities, and whom to call after hours if symptoms change.